Fouad Kandeel, MD
Endocrinology, Diabetes & Metabolism · Duarte, CANPI 1992761571
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,675 of the $4,031 with a category attached, or 91.2%. Vertex accounts for 91.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $3,694 and has fallen 98.0% since, to $73 in 2025.
Across 16 payments — averaging $251.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$4K
- Dexcom, Inc.$215
- Novo Nordisk$129
- Siemens Medical Solutions USA, Inc.$12
Across 13 payments — averaging $40,758 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$528K
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$3,67591%
- Food & beverage$2276%
- Education$1293%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 1 | $3,675 |
| Dexcom, Inc. | 10 | $215 |
| Novo Nordisk | 4 | $129 |
| Siemens Medical Solutions USA, Inc. | 1 | $12 |
How this compares
$4,031 in reported general payments places this provider in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 36 | $50,771 |
| JardianceEmpagliflozin | 17 | $25,700 |
| FarxigaDapagliflozin Propanediol | 11 | $14,373 |
| SynthroidLevothyroxine Sodium | 63 | $5,628 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $4,111 |
| Testosterone | 16 | $2,590 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $1,778 |
| Levothyroxine Sodium | 136 | $1,557 |
| Liothyronine Sodium | 38 | $1,252 |
| Atorvastatin Calcium | 108 | $1,237 |
| FenofibrateFenofibrate Nanocrystallized | 28 | $1,228 |
| Metformin Hcl | 112 | $1,080 |
| Ezetimibe | 14 | $842 |
| Potassium Chloride | 33 | $790 |
| Losartan Potassium | 83 | $744 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Duarte
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.